Health Technology AnGes, Inc. Business Summary
AnGes, Inc. engages in the research and development of gene-based medical products. It offers genetic medicines such as hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, and others. It is also involved in the research and development of medical equipment, which improves blood circulation by regenerating blood vessels and NfkB which controls various inflammations. The company was founded on December 17, 1999 and is headquartered in Ibaraki, Japan.
Financial Highlights
Dec 2020
JPY USD Revenue 39.99M 0.37M Gross Profit 12.06M 0.11M Operating income -5,599.39M -52.44M Income before tax -4,204.95M -39.38M Net income -4,209.51M -39.42M EBITDA -5,591.80M -52.37M Diluted EPS -35.32 -0.33 Dividends Per Share 0 0 Total Assets 38,354.61M 371.49M Total liabilities 5,674.93M 54.96M Total equity 32,679.67M 316.52M Operating cash flow -2,961.32M -27.73M Currency in JPY Currency in USD
Historical Data Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Revenue
514.26M
365.18M
610.05M
326.75M
39.99M
Gross Profit
281.91M
163.69M
418.87M
235.16M
12.06M
Operating income
-4,615.47M
-3,288.68M
-3,065.25M
-3,270.00M
-5,599.39M
Income before tax
-4,760.67M
-3,744.18M
-3,003.00M
-3,751.60M
-4,204.95M
Net income
-4,776.78M
-3,764.69M
-2,996.62M
-3,750.82M
-4,209.51M
EBITDA
-4,548.16M
-3,259.32M
-3,057.39M
-3,262.68M
-5,591.80M
Diluted EPS
-75.29
-49.38
-34.46
-35.81
-35.32
Dividends Per Share
0
0
0
0
0
Total Assets
4,539.20M
3,963.60M
8,050.67M
12,524.60M
38,354.61M
Total liabilities
669.81M
341.72M
316.21M
469.24M
5,674.93M
Total equity
3,869.38M
3,621.88M
7,734.45M
12,055.35M
32,679.67M
Operating cash flow
-4,983.69M
-2,991.22M
-2,522.50M
-2,179.91M
-2,961.32M
Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Revenue
4.73M
3.25M
5.52M
2.99M
0.37M
Gross Profit
2.59M
1.45M
3.79M
2.15M
0.11M
Operating income
-42.47M
-29.32M
-27.75M
-29.99M
-52.44M
Income before tax
-43.81M
-33.39M
-27.19M
-34.41M
-39.38M
Net income
-43.96M
-33.57M
-27.13M
-34.40M
-39.42M
EBITDA
-41.85M
-29.06M
-27.68M
-29.92M
-52.37M
Diluted EPS
-0.69
-0.44
-0.31
-0.32
-0.33
Dividends Per Share
0
0
0
0
0
Total Assets
38.91M
35.18M
73.37M
115.24M
371.49M
Total liabilities
5.74M
3.03M
2.88M
4.31M
54.96M
Total equity
33.17M
32.15M
70.49M
110.93M
316.52M
Operating cash flow
-45.86M
-26.67M
-22.83M
-19.99M
-27.73M
Valuation Measures
Dec 2020
PER -- ROA -16.54% ROE -18.81% Operating margin -13,999.17% Profit margin -10,524.30%
Key executives
President & Representative Director:
Ei Yamada
Director, Executive Officer & Manager-Finance:
Tetsuji Yoneo
Director & Manager-Drug Discovery Research:
Kazuo Suzuki
Executive Officer, Manager-R&D Promotion:
Hajime Watanabe
Manager-Accounting:
Jun Sakurai Shareholders
OrbiMed Advisors Private Equity (3.8%)
BlackRock Fund Advisors (1.0%)
Shionogi & Co., Ltd. (0.7%)
JPMorgan Asset Management (UK) Ltd. (0.4%)
MORISHITA RYUICHI (0.4%)
MAGARIBUCHI NAOKI (0.2%)
BlackRock Advisors (UK) Ltd. (0.1%)
TIAA-CREF Investment Management LLC (0.0%)
SSgA Funds Management, Inc. (0.0%)
Credit Suisse Asset Management (Schweiz) AG (0.0%)
Contact Details Website: http://www.anges.co.jp Address:
Saito Bio-Incubator, 1/F,
7-7-15 Saito-Asagi,
Osaka,
567-0085,
Japan
Phone:
+81.72.643.3590
Related Companies
Emendo Biotherapeutics, Inc.
AnGes USA, Inc.
AnGes Euro Ltd.
Competitors
Defence Therapeutics Inc Class A
Cellid Co., Ltd.
Sienna Biopharmaceuticals, Inc.
Athira Pharma, Inc.
Copyright © 2021 FactSet Research Systems Inc. All rights reserved.
Last Updated on 27 Sep, 2021
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more
